Paper40314865
The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches.
Sheikh M and 3 others. Med Oncol, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches. Papers, record 40314865. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40314865
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Oncolytic Virotherapy | Major topic |
| Neoplasms | Major topic |
| Immunotherapy | Major topic |
| Oncolytic Viruses | Major topic |
| Humans | |
| Animals | |
| Tumor Microenvironment | |
| Combined Modality Therapy |
Source PubMed
References157
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21276246 | Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense. | BMC Cancer | 2011 | https://conductscience.org/library/papers/21276246 | PubMed |
| 2 | 29658163 | A Novel Oncolytic Herpes Capable of Cell-Specific Transcriptional Targeting of CD133± Cancer Cells Induces Significant Tumor Regression. | Stem Cells | 2018 | https://conductscience.org/library/papers/29658163 | PubMed |
| 3 | 19587709 | Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. | Gene Ther | 2009 | https://conductscience.org/library/papers/19587709 | PubMed |
| 4 | 38543974 | Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth. | Vaccines (Basel) | 2024 | https://conductscience.org/library/papers/38543974 | PubMed |
| 5 | 37660142 | Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-γ promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors. | Cell Death Discov | 2023 | https://conductscience.org/library/papers/37660142 | PubMed |
| 6 | 27154307 | Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. | J Exp Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27154307 | PubMed |
| 7 | 30413828 | The clinical role of the TME in solid cancer. | Br J Cancer | 2019 | https://conductscience.org/library/papers/30413828 | PubMed |
| 8 | 32620755 | Cancer immunotherapy comes of age and looks for maturity. | Nat Commun | 2020 | https://conductscience.org/library/papers/32620755 | PubMed |
| 9 | 31350295 | The Tumor Microenvironment Innately Modulates Cancer Progression. | Cancer Res | 2019 | https://conductscience.org/library/papers/31350295 | PubMed |
| 10 | 29157300 | Prospects for combined use of oncolytic viruses and CAR T-cells. | J Immunother Cancer | 2017 | https://conductscience.org/library/papers/29157300 | PubMed |
| 11 | 33291506 | Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33291506 | PubMed |
| 12 | 32722981 | BNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains. | Autophagy | 2021 | https://conductscience.org/library/papers/32722981 | PubMed |
| 13 | 35860357 | Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/35860357 | PubMed |
| 14 | 39826543 | Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. | Cell | 2025 | https://conductscience.org/library/papers/39826543 | PubMed |
| 15 | 28929492 | Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer. | Int J Cancer | 2018 | https://conductscience.org/library/papers/28929492 | PubMed |
| 16 | 9242911 | Herpes simplex virus DNA replication. | Annu Rev Biochem | 1997 | https://conductscience.org/library/papers/9242911 | PubMed |
| 17 | 39048823 | TMEFF1 is a neuron-specific restriction factor for herpes simplex virus. | Nature | 2024 | https://conductscience.org/library/papers/39048823 | PubMed |
| 18 | 34903664 | Herpesvirus-mediated stabilization of ICP0 expression neutralizes restriction by TRIM23. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34903664 | PubMed |
| 19 | 38702343 | Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/38702343 | PubMed |
| 20 | 37641004 | The antitumor effect of oncolytic respiratory syncytial virus via the tumor necrosis factor-alpha induction and ROS-bax-mediated mechanisms. | BMC Cancer | 2023 | https://conductscience.org/library/papers/37641004 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41963598 | Apoptotic modulators enhance oncolytic virus-induced cytokine killing in acute myeloid leukaemia (AML). | Br J Cancer | 2026 | https://conductscience.org/library/papers/41963598 | PubMed |
| 41179287 | Reprogramming the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma: Therapeutic Targets and Innovations. | Oncol Res | 2025 | https://conductscience.org/library/papers/41179287 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40314865
GET https://conductscience.org/api/papers/v1/40314865/references?page=2